-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Pulmonary hypertension (PH) is a progressive disease characterized by increased pulmonary artery pressure and pulmonary vascular resistance
Pulmonary hypertension (PH) is a progressive disease characterized by increased pulmonary artery pressure and pulmonary vascular resistance
Pulmonary hypertension is a well-known complication in CTD, especially SSc
Pulmonary hypertension is a well-known complication in CTD, especially SSc 10% of SSc patients will develop PAH in their lifetime
Therefore, the early diagnosis of PH in CTD patients is challenging
The Special Working Group of the Sixth World PH Symposium proposed to change the hemodynamic definition of PH
Schematic diagram of the pulmonary vascular system
Schematic diagram of the pulmonary vascular system
Another challenging aspect of PAH-CTD is that patients often have a combination of different PH groups, so a more tailored treatment plan is required like idiopathic PAH patients
The main goal of future research should be to improve the prognosis of this vulnerable group by focusing on morbidity and mortality .
Echocardiogram and pulmonary hypertension
Echocardiogram and pulmonary hypertension
Risk assessment of pulmonary hypertension:
Original: Vonk MC, Vandecasteele E, van Dijk AP.
Leave a message here
